Oppenheimer says it expects sales of Cubist's (CBST -2.7%) Cubicin to surpass expectations this...

|By:, SA News Editor

Oppenheimer says it expects sales of Cubist's (CBST -2.7%) Cubicin to surpass expectations this year, and the firm thinks that the company's current 2012 guidance may be too conservative. It raises its price target to $49 from $45 and maintains an Outperform rating.